Cost-minimization analysis of the ferric carboxymaltose (i.v.) compared with iron sucrose (i.v.) in the treatment of anemia under suplementary health care perspective

Abstract

OBJECTIVE: Intravenous iron is more effective, better tolerated, and improves the quality of life to a greater extent than oral iron supplements. Ferric carboxymaltose (FCM) and iron sucrose (IS) are IV iron drugs available in the Brazilian market. Considering the scenario above, the purpose of the study is to perform a cost minimization analysis of FCM versus IS under the supplementary health setting. METHODS: Due to non-inferiority study design comparing both IV therapies, a cost-minimization analysis was conducted. Treatment expenditures were accounted considering drug acquisition costs and infusion related costs. Drug ex-factory prices were obtained from an official price list. Infusion fees were accessed through research conducted in 36 private hospitals distributed in service categories. Infusion fees ranged from BRL221.09 to BRL500.45, conservatively BRL221.09 was considered in the base case scenario. Deterministic one-way sensitivity analysis was performed. RESULTS: Treatment cost for FCM (BRL927.69) was lower than IS (BRL1,184.97), due to more infusions required for treatment with IS. The number and cost of the infusions were the most influential parameters in the analysis, and even with variations of ± 20% in all parameters, treatment results with FCM remained favorable. CONCLUSION: FCM represents a cost-saving option compared with other IV therapy alternative used in the management of anaemia in the Brazilian Supplementary Health System.